StreetAlpha.app
Home › Stocks › PDSB

PDS Biotechnology Corp (PDSB)

Healthcare
$0.89
▼ −3.28%
LAST CLOSE · NOV 17

PDS Biotechnology develops immunotherapies that aim to treat cancer and to prevent infectious diseases. It last closed at $0.89 on Nov 17, down 3.28% on the day. The average 12-month price target from 2 analysts is $4.50 (+403.5% from the last close), with a high of $5.00 and a low of $4.00.

AI Auto Pilots
Is PDSB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$32.3M
EPS (diluted)
−$0.54
Valuation
Market cap
$93.9M
105.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$15.2M
At Sep 30
Shareholder equity
$13.5M
Shares outstanding
105.0M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$16.9M−$16.9MFY2021FY2022: −$40.9M−$40.9MFY2022FY2023: −$42.9M−$42.9MFY2023FY2024: −$37.6M−$37.6MFY2024FY2025: −$34.5M−$34.5MFY2025

From PDSB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated PDSB in the past 90 days, not enough for a consensus
Average 12-month target
$4.50
▲ 403.5% upside

Based on 2 analysts who set a price target on PDSB in the past 90 days. The average target is $4.50, with a high of $5.00 and a low of $4.00, compared with the last close of $0.89.

$0$2$4$5PAST 16 TRADING DAYS12-MONTH TARGETSHIGH $5AVG $4.50LOW $4Sep 15LAST CLOSE+12 MO$0$2$4$5PAST 16 DAYSTARGETSHIGH $5AVG $4.50LOW $4Sep 15LAST CLOSE+12 MO
Highest target$5.00
Average target$4.50
Lowest target$4.00
Latest rating changes
B. Riley SecuritiesReiterated
Oct 29Buy$4
HC Wainwright & Co.Target lowered
Sep 8Buy$7 → $5
HC Wainwright & Co.Reiterated
Aug 26Buy$7
HC Wainwright & Co.Maintained
Aug 13Buy$7
DateFirmActionRatingPrice target
Oct 29B. Riley SecuritiesReiteratedBuy$4
Sep 8HC Wainwright & Co.Target loweredBuy$7 → $5
Aug 26HC Wainwright & Co.ReiteratedBuy$7
Aug 13HC Wainwright & Co.MaintainedBuy$7
Loading…

Technical Analysis

PDSB · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 32% below its 20 day and 13% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 42). The nearest support is the swing low (Jun 16) at $0.87, and the nearest resistance the Pivot at $0.92.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 18.8%/day
Key levels
$1.7952 week high+101.1%
$1.1820 day average+32.6%
$1.06Swing high (Sep 16)+19.1%
$1.0150 day average+13.5%
$0.95Pivot R1+6.7%
$0.92Pivot+3.4%
$0.89Last close
$0.87Swing low (Jun 16)−2.2%
$0.86Pivot S1−3.4%
$0.84200 day average−5.6%
$0.78100 day average−12.4%
$0.2052 week low−77.5%
Indicators
RSI (14)41.52Middle of its rangeNeutral
MACD-0.04Below its signal lineBearish
Stochastic14.4Near the bottom of its rangeOversold
ADX (14)29.1Trending down
Williams %R-86.0Oversold below −80, overbought above −20Oversold
CCI (20)-102.3Oversold below −100, overbought above 100Oversold
Rate of change−36.6%Change over 10 sessionsBearish
ATR (14)$0.17Typical daily range, 18.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for PDSB

What happened before

See how PDSB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PDSB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PDSB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PDSB in the last 90 days.

Loading…

See today’s whale options flow across the market →

PDSB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲32 buying vs 18 selling
  • ▲Held by funds +3.1 pts
  • ▲Funds holding +10
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6252+19.2%
In funds' top 1000–
Held by funds10.5%7.3%+3.1 pts
New / increased18 / 1414 / 13+18.5%
Reduced / sold out12 / 67 / 4+63.6%
Put/call ratio0.290.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PDSB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PDSB is in one of them and how their past PDSB trades turned out.

PDSB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PDSB in an article yet. Here's the latest on the wider market.

About PDS Biotechnology

PDS Biotechnology is a clinical stage immunotherapy company based in Princeton, New Jersey. It is developing cancer treatments built on its Versamune platform, including a combination with an interleukin 12 antibody drug conjugate, and an Infectimune T cell activator for preventive vaccines against infectious agents. The Versamune platform is a lipid nanoparticle designed to stimulate the immune system's killer and helper T cells. Its investigational products are aimed at patients with cancer and at preventive vaccines for infectious diseases.

Headquarters
Princeton, NJ